| Description | Recainam is a novel, orally available compound with potent class I antiarrhythmic activity. |
| In vivo | Recainam was administered at a loading dose of 4.5 mg/kg/hour over 40 minutes, followed by a maintenance infusion of 0.9 mg/kg/hour for 23 hours and 20 minutes. The mean frequency of total VPCs decreased by 92.6% and the mean frequency of runs decreased by 99.9% during the maintenance infusion. Suppressions of > or = 70% of total VPCs and > or = 90% of runs were maintained over the 23-hour, 20-minute maintenance infusion period in 16 of the 18 patients. During the maintenance infusion, hourly group plasma Recainam concentrations ranged from mean +/- SD 2.6 +/- 0.7 to 3.4 +/- 0.9 micrograms/ml. The following pharmacokinetic parameters were obtained: terminal elimination half-life, 5.0 +/- 0.8 hours; systemic clearance, 0.27 +/- 0.08 liter/hour/kg; and central and steady-state volume of distribution, 0.32 +/- 0.11 and 1.4 +/- 0.4 liter/kg, respectively.[2] |
| molecular weight | 263.38 |
| Molecular formula | C15H25N3O |
| CAS | 74738-24-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (170.86 mM) |
| References | 1. Scatina JA, et al. Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug. Biopharm Drug Dispos. 1990;11(5):445-461. 2. Anderson JL, et al. Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia. Am J Cardiol. 1993;71(8):686-694. 3. Colatsky TJ, et al. Cellular electrophysiology of the new antiarrhythmic agent recainam (Wy-42,362) in canine cardiac Purkinje fibers. J Cardiovasc Pharmacol. 1987;9(4):435-444. 4. Tai YT, et al. Electrophysiologic effects and antiarrhythmic efficacy of recainam in patients with supraventricular tachycardia. J Cardiovasc Pharmacol. 1991;17(2):310-315. |